Low dose oral interferon alpha 2a in HIV-1 seropositive patients: A double-blind, placebo-controlled trial

Biotherapy

Volumn 11, Issue 4, 1998, Pages 229-234

  Wright, Stephen E ^a,b,c   Hutcheson, David P ^a   Cummins, Joseph M ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Animal Agricultural Consulting   (United States)

^c Amarillo Biosciences Inc   (United States)

Author keywords

HIV infections; Interferon alpha 2a

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON;

ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

ANIMALS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; HIV SEROPOSITIVITY; HIV-1; HUMANS; INTERFERON ALFA-2A; SURVIVAL RATE;

EID: 0032414220     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008050000064     Document Type: Article

References (17)

1. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T- lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983: 220: 868-71.
2. Popovic M, Sarngadharan MG, Read E. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984; 224: 497-500.
3. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-1II) from patients with AIDS and at risk for AIDS. Science 1984: 224: 500-3.
4. Trown PW. Wills RJ, Kamm JJ. The preclinical development of Roferon-A. Cancer 1986; 57: 1648-56.
5. Cummins JM, Hutcheson DP, Cummins MJ, Georgiades JA, Richards AB. Oral therapy with human Interferon alpha in calves experimentally injected with infectious bovine rhinotracheitis virus. Arch Immunol Ther Exp (Warsz) 1993; 41: 193-7.
6. Cummins LM, Tompkins MB. Olsen RG. Tompkins WA. Lewis MO. Oral use of human alpha Interferon in eats. J Biol Response Mod 1988; 7: 513-23.
7. Centers for Disease Control, U.S. Department of Health and Human Services: (1986) Classification system for human T-lympholropic virus type Ill/lymphadenopathy-associated virus infections. Annuals of Internal Medicine 105. 234-37.
8. Karnofsky DA. Ahelmann WM. Carver LF. Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948: 1: 634-56.
9. Statistical Analysis System (SAS) User's Guide: (1992) Statistics Version 6.01. Gary, N.C. SAS Institute.
10. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-30.
11. Fischl MA. Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebocontrolled trial. New Engl J Med 1987: 317: 185-91.
12. Lelic PN, Reesink HW. Bakker E, Huisman JG , ten Veen JH. Clinical importance of HIV antigen and anti-HIV core markers in persons infected with HIV |letter]. New Engl J Med 1988; 318: 1204-5.
13. Interferon Alpha Study Group. Arandomized placebocontrolled trial of recombinant human Interferon alpha 2a in patients with AIDS. J Acquir Immune Detic Syndr 1988; 1: 111-18.
14. Sperber SJ, Gocke DJ, Haberzettl CA. Pestka S. Low-dose oral recombinant interferon-alpha A in patients with HIV-1 infection: a blind pilot study. AIDS 1993; 7: 693-7.
15. Lane HC. Davey V, Kovacs JA, et al. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med 1990: 112: 805-1.
16. Kaiser G, Jaeger H, Birkmann J, Poppinger J, Cummins JM, Gallmeier WM. Low-dose oral natural human interferon-alpha in 29 patients with HIV-1 infection: a double-blind, randomized, placebo-controlled trial [published erratum appears in AIDS 1992 Sep; 6(9): following 1051]. AIDS 1992: 6: 563-9.
17. Hulton MR, Levin DL, Freedman LS. Randomized, placebocontrolled, double-blind study of low-dose oral interferonalpha in HIV-1 antibody positive patients. J Acquir Immune Defic Syndr 1992; 5: 1084-90.